David Morrison

David Morrison

Auto-generated profile, based on publicly available information

David Morrison

Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SZSirui Zhou
Sirui Zhou
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
TNTomoko Nakanishi
Tomoko Nakanishi
DMDavid R. Morrison
David R. Morrison
JAJonathan Afilalo
Jonathan Afilalo
JRJ. Brent Richards
J. Brent Richards

20 February 2023 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SYSatoshi Yoshiji
Satoshi Yoshiji
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
TLTianyuan Lu
Tianyuan Lu
JWJulian Daniel Sunday Willett
Julian Daniel Sunday Willett
CSChen-Yang Su
Chen-Yang Su
JRJ. Brent Richards
J. Brent Richards

3 November 2022 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
GPGundula Povysil
Gundula Povysil
JKJack A. Kosmicki
Jack A. Kosmicki
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
TDTheodore Drivas
Theodore Drivas
JRJ Brent Richards
J Brent Richards
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.

26 November 2021 in Science Advances
Verified
Journal Article
Open access
EBElsa Brunet-Ratnasingham
Elsa Brunet-Ratnasingham
SASai Priya Anand
Sai Priya Anand
PGPierre Gantner
Pierre Gantner
ADAlina Dyachenko
Alina Dyachenko
GMGaël Moquin-Beaudry
Gaël Moquin-Beaudry
DKDaniel Kaufmann
Daniel Kaufmann
Statistical models of plasma immunovirological features validate SARS-CoV-2 vRNA as an early predictor of COVID-19 mortality.

16 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
EBElsa Brunet-Ratnasingham
Elsa Brunet-Ratnasingham
SMSacha Morin
Sacha Morin
HRHaley E. Randolph
Haley E. Randolph
MLMarjorie Labrecque
Marjorie Labrecque
JBJustin Bélair
Justin Bélair
DKDaniel Kaufmann
Daniel Kaufmann
Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized patients with COVID-19. Integrated analysis using k-means reveals four patient clusters in a discovery cohort: mechanically ventilated critically-ill cases are subdivided into good prognosis and high-fatality clusters (reproduced in a validation cohort), while non-critical survivors segregate into high and low early antibody responders. Only the high-fatality cluster is enriched for transcriptomic signatures associated with COVID-19 severity, and each cluster has distinct RBD-specific antibody elicitation kinetics. Both critical and non-critical clusters with delayed antibody responses exhibit sustained IFN signatures, which negatively correlate with contemporaneous RBD-specific IgG levels and absolute SARS-CoV-2-specific B and CD4+ T cell frequencies. These data suggest that the “Interferon paradox” previously described in murine LCMV models is operative in COVID-19, with excessive IFN signaling delaying development of adaptive virus-specific immunity.

13 July 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
HWHilde Skuterud Wik
Hilde Skuterud Wik
SKSusan R. Kahn
Susan R. Kahn
HEHenry Eriksson
Henry Eriksson
DMDavid Morrison
David Morrison
WGWaleed Ghanima
Waleed Ghanima
Per Morten SandsetPer Morten Sandset
Per Morten Sandset
Background Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to warfarin reduces the risk of post-thrombotic syndrome (PTS) after deep vein thrombosis (DVT), but this has not been evaluated for oral direct thrombin inhibitors. Objectives To compare the long-term prevalence of PTS, recurrent venous thromboembolism (VTE), and health-related quality of life (HRQoL) in patients with acute DVT and/or pulmonary embolism (PE), randomized to treatment with dabigatran or warfarin in the phase III RE-COVER studies. Methods We conducted a cross-sectional follow-up study of patients randomized in Canada, Norway, and Sweden. PTS was assessed by the patient-reported Villalta scale (PRV) and HRQoL by EQ-5D and VEINES-QOL/Sym. Results We included 349 patients between December 2015 and November 2018; 166 were treated with dabigatran and 183 with warfarin. DVT (+/− PE) was index event in 255 patients, whereas 94 patients had PE only. Mean time from index event was 8.7 (standard deviation 1.4) years. PTS was diagnosed in 63% of patients with DVT and in 46% of patients with PE only, and did not differ between the treatment groups; the crude odds ratio (OR) for PTS in patients treated with dabigatran compared with warfarin was 1.1 (95% confidence interval [CI] 0.6–1.8) after DVT and 1.2 (95% CI 0.5–2.6) after PE only. The prevalence of recurrent VTE was 21% in both treatment groups. HRQoL scores did not differ between groups. Conclusion In this long-term cross-sectional study, the prevalence of PTS, recurrent VTE, and HRQoL were similar in patients treated with dabigatran and warfarin.